NCT01364051View on ClinicalTrials.gov

Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

May 25, 2011

Primary Completion Date

June 6, 2019

Study Completion Date

March 19, 2026

Conditions
Metastatic MelanomaRefractory Malignant Solid NeoplasmStage IV Cutaneous Melanoma AJCC v6 and v7Unresectable Malignant Solid Neoplasm
Interventions
DRUG

Cediranib

Given PO

DRUG

Cediranib Maleate

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Selumetinib

Given PO

DRUG

Selumetinib Sulfate

Given PO

Trial Locations (2)

55905

Mayo Clinic in Rochester, Rochester

32224-9980

Mayo Clinic in Florida, Jacksonville

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH